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Abstract
Background: Biomarkers that predict clinical response, tumor recurrence or patient survival are
severely lacking for most cancers, particularly for oral and pharyngeal cancer. This study examines
whether gene-promoter methylation of tumor DNA correlates with survival and recurrence rates
in a population of patients with oral or pharyngeal cancer.
Methods: The promoter methylation status of the DNA repair gene MGMT and the tumor
suppressor genes CDKN2A and RASSF1 were evaluated by methylation-specific PCR in 88 primary
oral and pharyngeal tumors and correlated with survival and tumor recurrence. Quantitative
MGMT methylation was also assessed.
Results: 29.6% of the tumors presented with MGMT methylation, 11.5% with CDKN2A methylation
and 12.1% with RASSF1 methylation. MGMT promoter methylation was significantly associated with
poorer overall and disease-free survival. No differences in methylation status of MGMT and RASSF1
with HPV infection, smoking or drinking habits were observed. A significant inverse trend with the
amount of MGMT methylation and overall and disease-free survival was observed (ptrend = 0.002
and 0.001 respectively).
Conclusion: These results implicate MGMT promoter methylation as a possible biomarker for
oral and pharyngeal cancer prognosis. The critical role of MGMT in DNA repair suggests that
defective DNA repair may be correlative in the observed association between MGMT promoter
methylation and tumor recurrence. Follow-up studies should include further quantitative MSP-PCR
measurement, global methylation profiling and detailed analysis of downstream DNA repair genes
regulated by promoter methylation.
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Oral and pharyngeal squamous cell carcinoma is the most
common malignant neoplasm of the head and neck
region [1]. An estimated 34,360 new patients were diag-
nosed with squamous cell carcinoma of the head and neck
and 7,550 deaths occurred in the U.S. in 2007, accounting
for 2-3% of all malignancies [2]. About 30-50% of oral
and pharyngeal cancer patients will develop a recurrence
and/or a second primary tumor within two decades of the
initial diagnosis. The five-year survival rate for oral cavity
cancer has changed little between 1975 and 2002, approx-
imately 48% [2]. Despite the progress made in early detec-
tion and therapy, early predictors of cancer recurrence at
time of diagnosis are still missing for oral and pharyngeal
cancer.
Epigenetic changes in cancer have traditionally been eval-
uated by measuring the status of CpG island cytosine
methylation of a particular gene, such as MGMT [3]. It has
been well-documented in cell lines, xenografts and in
clinical trials, that methylation at discrete regions within
CpG islands of a given gene promoter results in gene
silencing and therefore prevents expression of the corre-
sponding gene [3]. Several genes (oncogenes, tumor sup-
pressor genes, DNA repair genes and growth control
genes) have been shown to have an aberrant methylation
profile (promoter hypermethylation) in tumors as com-
pared to normal tissue or blood cells or cells in bodily flu-
ids [4-6]. The altered DNA methylation landscape of the
cancer epigenome is not limited to promoter hypermeth-
ylation of select genes, but also includes global
hypomethylation as a prelude to oncogene activation and
genome instability [7-9].
It has been suggested that aberrant methylation patterns
could therefore act as a selective factor on neoplastic cells,
influencing patients' survival and prognosis, particularly
if methylation affects expression of a tumor suppressor
gene such as CDKN2A, RASSF1 or a DNA repair gene such
as MGMT. For example, aberrant gene hypermethylation
of CDKN2A, p14ARF [10], RASSF1 [11-13] and the DNA
repair gene MGMT [3] have been reported in tumor tissue
of oral cavity cancer patients (see Table 1 for a more com-
prehensive list of genes methylated in oral cancers). In
addition, promoter methylation of CDKN2A, MGMT,
DAPK1, and CDH1 has been studied in relation to head
and neck cancer survival [14-17]. However, the role of
hypermethylation on outcome in oral and pharyngeal
cancer patients, a special subset of head and neck cancers,
has not yet been addressed.
Oral and pharyngeal cancers are for the large part squa-
mous cell histological types, and are often anatomically
grouped with head and neck cancers. Although the head
and neck tumors have been historically grouped together
due to similar etiology, the oral cavity, pharynx and larynx
are unique structures with different functions and possi-
bly different sensitivities to carcinogens, especially alco-
hol and tobacco. Human Papillomavirus is another
etiologic agent involved in oral and pharyngeal tumors
[18,19]. In the study described herein, we tested the asso-
ciation between promoter methylation and survival in a
cohort of 88 oral and pharyngeal cancer patients, focusing
on three target genes: the DNA repair gene MGMT and the
tumor suppressor genes CDKN2A and RASSF1.
Methods
Study population
A database of head and neck cancer cases was established
in June 2004 at the University of Pittsburgh Medical
Center [19] for patients undergoing surgical resection of
their tumors between November 1992 and February
1997. Demographics, smoking and alcohol use, family
history, tumor site, clinical characteristics of the initial pri-
mary tumor and subsequent tumors, follow-up data (such
as disease outcome and time to next disease occurrence)
through June 2007 were obtained from the University of
Pittsburgh Tumor Registry and from the review of clinical
charts. Patients' clinical and demographic information
was re-verified from each patient's original de-identified
and coded questionnaires, pathology and surgical reports.
This database contains clinical, treatment and follow-up
information for the first surgical resection at the time of
enrollment and all subsequent resections for all patients
enrolled in the study. Tumor site, histology, stage and
grade were classified according to the American Joint
Committee on Cancer (AJCC) ICD9 codes, ICD-morphol-
ogy, stage and grade classification, respectively. Samples
were collected under IRB approval of the University of
Pittsburgh Head and Neck SPORE tissue bank. All tumors
samples were consented by the SPORE tissue bank and
IRB approval is for data analysis as described herein.
Information on 88 subjects undergoing surgical resection
of their first primary tumors was selected from the original
database; HPV status was determined for all the tumors by
PCR as previously described [19]. Sites of the oral cavity
included cheek, retromolar area, alveolar ridge, oral
tongue, palate, floor of mouth and overlapping lesions of
other and unspecified parts of the mouth. The oropharynx
included sites involving the base of tongue, soft palate,
tonsil and overlapping lesions of the oral cavity and phar-
ynx.
Methylation-specific PCR
Previously extracted DNA from tumors was utilized in this
study. DNA was isolated from primary fresh-frozen tumor
tissue by guanidine thiocyanate extraction using the com-
mercially available IsoQuick kit (MicroProbe, Garden
Grove, CA) as we have described previously [20]. Methyl-Page 2 of 11
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Gene Cancer type Method for methylation analysis Reference
TSC2 Oral squamous cell carcinoma 
(OSCC)
COBRA [44]
CDKN2A, p14ARF OSCC MSP [10]
MGMT Head & Neck squamous cell 
carcinoma (HNSCC)
MSP [3]
RASSF1A Betal-associated oral carcinoma MSP [13]
p16INK4a, p15, MLH1, MGMT, E-CADHERIN OSCC Restriction multiplex PCR [29]
p16INK4a, RASSF1A, DAPK Salivary adenoid cystic carcinoma MSP [30]
MGMT HNSCC MSP [21]
p16INK4a HNSCC MSP [22]
MGMT, p16INK4a, MLH1 HNSCC MSP [23]
CNKN2, CDH1, MGMT, DAPK, DBC1, p14, CDKN2B, 
RARB, RASSF1A, MLH1, p73, DCC, FHIT, SERPINB5
HNSCC &/or OSCC MSP, PCR-based restriction assay and/
or bisulfite sequencing
[11]
p16INK4a, CYCLIN A1, RARB, E-CADHERIN, MGMT, 
STAT1, ATM, MLH1, TIMP3
SCC of the oral cavity or 
oropharynx
pryosequencing [26]
RASSF2 OSCC MSP [45]
RECK OSCC MSP [46]
ATM HNSCC MSP [47]
p16INK4a, CYTOGLOBIN, CYCLIN A1 OSCC pyrosequencing [35]
MLH1 HNSCC MSP [15]
p16INK4a, MGMT, DAPK, E-CADHERIN Laryngeal and hypopharyngeal 
cancer
MSP [24]
CYTOGLOBIN Oral or oropharyngeal squamous 
cell carcinoma
pyrosequencing [48]
RIZ1 Nasopharyngeal carcinoma MSP [49]
CDKN2A OSCC [50]
p16INK4a, p14ARF, MGMT, RB1, PTEN, p27KIP1 OSCC MSP [51]
APC OSCC MSP [52]
CDH1 HNSCC MSP [53]
p16INK4a, DAPK, E-CADHERIN, RASSF1A HNSCC MSP [54]
TIMP3, CDH1 HNSCC MSP [55]Page 3 of 11
(page number not for citation purposes)
BMC Cancer 2009, 9:354 http://www.biomedcentral.com/1471-2407/9/354ation-specific PCR was used for the analysis of MGMT,
RASSF1 and CDKN2A promoter methylation as described
[3,21-24] using the Zymo Research EZ DNA Methylation-
Gold reagents (ZYMO Research) according to the manu-
facturer's instructions. The primers used to assess MGMT
promoter methylation status were: Methylated MGMT
allele - tttcgacgttcgtaggttttcgc and gcactcttccgaaaacgaaacg;
annealing temperature = 58°C; expected amplicon size =
81 bp. Un-methylated MGMT allele - tttgtgttttgatgtttgtag-
gtttttgt and aactccacactcttccaaaaacaaaaca; annealing tem-
perature = 58°C; expected amplicon size = 93 bp [3]. The
primer sequences to assess RASSF1 and CDKN2A methyl-
ation status were previously described [17,25]. A DNA
methylated control using either Methylated or Unmethyl-
ated DNA (Chemicon; Millipore) is included in all the
DNA modification and PCR reactions. PCR reaction prod-
ucts were then separated on 4% agarose gels containing
ethidium bromide with 100 bp DNA Ladder Markers
(Bioline) and examined under ultraviolet illumination to
identify the distinct bands. Each PCR reaction was run in
duplicate.
Quantitative Methylation Analysis
To determine the degree of methylation among subjects
found to have MGMT hypermethylation by MSP, quanti-
tative methylation analysis was performed using a pyrose-
quencing methylation assay [26,27]. DNA samples that
yielded a positive result in the MSP assay were then sub-
jected to a quantitative methylation test using the Pyro-
Mark MGMT ID system, as per the manufacturer's
instructions (Biotage, Inc.). Briefly, DNA was bisulfite
treated using the Zymo Research EZ DNA Methylation-
Gold reagents as indicated above. The treated DNA was
amplified by PCR with MGMT-specific primers and
twenty microliters of the amplicon was then subjected to
pyrosequencing using the Biotage PyroMark Q24 System.
CpG site quantification was performed with the Biotage
methylation Software PyroQ-CpG™. The average percent
methylation for MGMT was calculated from direct meas-
urement of the percentage of methylation at five individ-
ual CpG sites.
Statistical analyses
Follow-up, demographic, clinical and laboratory data for
the study population was extracted from the head and
neck database and imported to a statistical software pack-
age for analysis. Statistical analyses were performed using
the Intercooled STATA (version 8.2) software (StataCorp.
LP, College Station TX). Vital status and recurrence were
the primary statistical endpoints for survival. Overall sur-
vival was defined as the time period between the surgical
resection of the initial primary tumor and death. Disease-
free survival was defined as the time period between the
surgical resection of the initial primary and tumor recur-
rence. All patients lost to follow-up were censored. Kap-
lan-Meier survivor functions for overall and disease-free
survival were generated using STATA. The log-rank statis-
tic was used to test the equality of survivor functions. Mul-
tivariable Cox proportional hazards models were created
for overall and disease-free survival for both MSP data for
CDKN2A, RASSF1A, and MGMT; and quantitative MGMT
methylation data generated from the pyrosequencing
assay. For the quantitative data models, degree of MGMT
methylation status was classified as unmethylated, meth-
ylation index ≤ 6.9%, and methylation index > 6.9%,
based on the median of the whole population, and was
analyzed as a categorical variable. Age, race, gender, smok-
ing status, alcohol consumption, treatment and stage at
diagnosis were considered for inclusion in the model. All
covariates with P < 0.25 were retained in the final model.
p16INK4a Oral epithelial dysplasia MSP [56]
RARB, MGMT, RASSF1, E-CADHERIN Salivary gland carcinoma pyrosequencing [57]
MGMT, p16INK4a OSCC MSP [31]
RASSF1A, RASSF2A, HIN-1 OSCC PCR-denaturing HPLC [12]
MLH1, MSH2 OSCC MSP [58]
RUNX3 OSCC MSP [59]
LINE-1 OSCC COBRALINE-1 [60]
SFRP1, SFRP2, SFRP5 OSCC MSP [61]
miR-137 OSCC COBRA and bisulfite sequencing [62]
Table 1: Promoter methylation of genes in Oral cancer (Continued)Page 4 of 11
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Patient demographics
The description of the population under study is reported
in Table 2. As expected from the epidemiology of oral and
pharyngeal cancer, there was a 2:1 male:female ratio. The
majority of the subjects were ever smokers (87.5%) and
ever drinkers (81.8%). The average follow up was 65.8 ±
48.9 months. During the follow-up, 42.0% of the patients
developed a recurrence, and 53.4% died. More than half
of the patients (59%) were in stage III or IV at diagnosis;
half of the patients were treated with surgery alone, half
with a combination of surgery and radiotherapy and/or
chemotherapy.
MGMT, CDKN2A and RASSF1 methylation status and 
outcome
Promoter methylation at MGMT was seen in 29.6% (26/
88) of the tumors, 11.5% (7/61) showed CDKN2A meth-
ylation and 12.1% (8/66) RASSF1 methylation. The distri-
bution of methylation status in the three genes studied
according to several personal and clinical characteristics is
presented in Table 3. Methylation of CDKN2A was signif-
icantly more frequent in never drinkers, and in less severe
stages at diagnosis. Conversely, no association was
observed between methylation status of MGMT, or
RASSF1 and any of the variables analyzed, including
smoking or drinking habits, stage at diagnosis or family
history of cancer. MGMT promoter methylation was sig-
nificantly inversely associated with overall survival (p =
0.049; Figure 1A) and disease-free survival (p = 0.013; Fig-
ure 1B). A non-significant association of promoter hyper-
methylation and both recurrence and survival was
observed for CDKN2A (data not shown).
Table 2: Description of the study population
Characteristic Study Population
n (%)





Never smoker 11 (12.5%)
Ever smoker 77 (87.5%)
Alcohol Use
Never drinker 16 (18.2%)






Adenoid Cystic 1 (1.1%)
Mucoepidermoid 2 (2.3%)
Anatomic site








Surgery only 44 (50.0%)
Surgery and radiotherapy 39 (44.3%)
Surgery and chemoradiation 5 (5.7%)
MGMT promoter methylation statusFigure 1
MGMT promoter methylation status. Methylation at 
the MGMT promoter was determined by methylation spe-
cific PCR, followed by gel electrophoresis. Shown are the 
plots of (A) overall patient survival time (months) and (B) 
disease-free survival time (months), according to MGMT 
methylation status (unmethylated or methylated).Page 5 of 11
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was significantly inversely associated with overall survival
(HR = 2.17, 95% CI: 1.11-4.23), after adjustment for age
and stage at diagnosis, smoking, alcohol consumption;
and disease-free survival (HR = 3.49, 95% CI: 1.62-7.52),
adjusting for age and stage at diagnosis, smoking, alcohol
consumption, treatment. There was no association
between hypermethylation of CDKN2A or RASSF1 and
overall or disease-free survival (Table 4).
For a subset of the population (n = 61) information on
methylation status of all three genes was available (Table
5). Only 1.6% of the samples showed simultaneous
hypermethylation of MGMT, CDKN2A, and RASSF1,
while 8.2% of the samples reported methylation in two of
the investigated genes. These frequencies do not diverge
significantly from expected frequencies derived from a
random combination of methylated genes.
All of the HPV-positive tumors carried non-methylated
CDKN2A promoters, while no differences in methylation
status of MGMT and RASSF1 with HPV infection was
observed.
Methylation status in peripheral blood
No RASSF1 or CDKN2A methylation was observed in
DNA extracted from peripheral blood lymphocytes, while
one sample (1.3%), a T4N0 M0 (stage IVa) squamous
cancer of the oral cavity, showed MGMT methylation in
the DNA sample obtained from blood cells.
Table 3: Description of methylation status by methylation-specific PCR (MSP) in relation to main demographic and clinical 
parameters
MGMT Methylation (%) RASSF1 methylation (%) CDKN2A methylation (%)
Gender
Male 14/56 (25.0%) 4/44 (9.1%) 5/40 (12.5%)
Female 12/32 (37.5%) 4/22 (18.2%) 2/21 (9.5%)
Smoking status
Never smoker 5/11 (45.5%) 0/9 (0.0%) 2/8 (25.0%)
Ever smoker 21/77 (27.3%) 8/57 (14.0%) 5/53 (9.4%)
Alcohol use
Never drinker 4/16 (25.0%) 0/12 (0.0%) 4/12 (33.3%)*
Ever drinker 22/72 (30.6%) 8/54 (14.8%) 3/49 (6.1%)*
Family history
Negative 11/41 (26.8%) 3/35 (8.6%) 4/30 (13.3%)
Positive 15/47 (31.9%) 5/31 (16.1%) 3/31 (9.7%)
Histology
Squamous 24/85 (28.2%) 8/65 (12.3%) 7/60 (11.7%)
Other 2/3 (66.7%) 0/1 (0.0%) 0/1 (0.0%)
Anatomic site
Oral cavity & lip 12/50 (24.0%) 5/37 (13.5%) 6/35 (17.1%)
Oropharynx 14/38 (36.8%) 3/29 (10.3%) 1/26 (3.8%)
Stage at diagnosis
Local (I, II) 11/36 (30.6%) 5/27 (18.5%) 4/26 (15.4%)*
Advanced (III, IV) 15/52 (28.8%) 3/39 (7.7%) 3/35 (8.6%)*
Treatment
Surgery only 9/44 (20.5%) 3/26 (11.5%) 3/24 (12.5%)
Surgery and radiotherapy 16/39 (41.0%) 5/40 (12.5%) 4/37 (10.8%)
Surgery and chemoradiation 1/5 (20.0%) ----- -----
HPV
Negative 18/67 (26.9%) 7/47 (14.9%) 7/45 (15.6%)
Positive 8/21 (38.1%) 1/19 (5.3%) 0/7 (0.0%)
* Statistically significant (α = 0.05)Page 6 of 11
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We were able to obtain pyrosequencing results for 20/26
samples that tested positive for MGMT promoter methyl-
ation by MSP (3 samples had no remaining DNA; and 3
resulted as "not determined"). The median MtI value was
6.9% methylation, which ranged from 0.6% to 52.6%.
Patients with high levels of MGMT promoter methylation
(> 6.9%; n = 10) showed an overall significant decreased
survival relative to patients with no MGMT hypermethyl-
ation (HR = 4.38, 95% CI: 1.78-3.91), after adjustment for
age, gender, alcohol consumption, and stage at diagnosis.
There was no association between the presence of less
than or equal to 6.9% methylation (n = 10) and overall
survival (HR = 1.52, 95% CI: 0.59-3.91). A significant
inverse trend in survival with the amount of MGMT meth-
ylation was observed (ptrend = 0.002; Table 4). Similar dif-
ferences were observed in the Kaplan-Meier survival
function (p = 0.025; Figure 2A).
The degree of MGMT hypermethylation was also associ-
ated with poorer disease-free survival (ptrend = 0.001).
Those with the highest degree of MGMT hypermethyla-
tion experienced poorer disease-free survival (HR = 5.46,
95% CI: 1.75-17.00) than patients with ≤ 6.9% MGMT
methylation (HR = 3.03, 95% CI: 1.24-7.44) relative to
subjects with no MGMT hypermethylation. A positive
inverse trend was observed between the degree of MGMT
methylation and disease-free survival (ptrend = 0.001).
These results were observed in the unadjusted Kaplan-
Meier survival function as well (p = 0.046; Figure 2B).
Discussion
Current research has shown that a number of tumor sup-
pressor genes may be inactivated not only by genetic
mechanisms such as deletions or point mutations, but
also by hypermethylation or other similar epigenetic
mechanisms [28] (see Table 1). While it is unclear
whether environmental factors are responsible for gene
hypermethylation, it has become clear that the presence of
hypermethylation could be one of the predictors of prog-
nosis [14-17,29,30]. We have analyzed here promoter
methylation in three genes that have been involved in
head and neck cancer prognosis, but focused our atten-
tion on the predictive values of these epigenetic events in
cancer of the oral cavity and pharynx. Our results suggest
that MGMT hypermethylation is one of the prognostic
factors in oral and pharyngeal cancer patients' survival;
similar findings were reported for head and neck patients
in general by some authors [21,23] but not by others [24].
Among the strengths of our study is the well characterized
population of oral and pharyngeal cancers, which has
detailed baseline epidemiological data on risk factors
including HPV testing and complete therapy information,
as well as complete follow-up data. In addition, a compar-
ison between tissue and peripheral blood methylation
from the same patient was possible because of the availa-




Unmethylated 1 (reference) 1 (reference) 1 (reference)
Methylated 2.17 (1.11-4.23)A 1.41 (0.35-5.75)C 0.88 (0.20-3.84)C
< 6.9% Methylated 1.52 (0.59-3.91)B not evaluated not evaluated
≥ 6.9% Methylated 4.38 (1.78-10.76)B not evaluated not evaluated
Test of trend p = 0.002 --- ---
Disease-Free Survival
Unmethylated 1 (reference) 1 (reference) 1 (reference)
Methylated 3.49 (1.62-7.52)D 2.57 (0.47-14.12)C 2.54 (0.82-7.93)C
< 6.9% Methylated 3.03 (1.24-7.44)B not evaluated not evaluated
≥ 6.9% Methylated 5.46 (1.75-17.00)B not evaluated not evaluated
Test of trend p = 0.001 --- ---
A Adjusted for age, smoking, alcohol use, and stage at diagnosis
B Adjusted for age, gender, alcohol use, and stage at diagnosis
C Adjusted for age, alcohol use, and stage at diagnosis
D Adjusted for age, smoking, alcohol use, treatment, and stage at diagnosis
Table 5: Proportion of promoter hypermethylation in MGMT, 
CDKN2A and RASFF1 in oral and pharyngeal cancer tissues
N of subjects (%)
N = 61
MGMT CDKN2A RASSF1
35 (57.3) - - -
13 (21.3) + - -
5 (8.2) - + -
2 (3.3) - - +
4 (6.6) + - +
1 (1.6) + + -
0 (0.0) - + +
1 (1.6) + + +
+: methylated
-: unmethylatedPage 7 of 11
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this study is that although this is the largest oral and pha-
ryngeal cancer study using follow up data in relation to
promoter methylation, the sample size is still relatively
small. Additionally, the tumor samples used were not
microdissected, leaving open the possibility of contami-
nation from surrounding normal tissue and stroma,
although previous studies have demonstrated that MGMT
is not generally methylated in normal head and neck tis-
sue [31,32].
In our cohort of patients, a methylation frequency similar
to that reported in the literature was observed for MGMT
(25-52%) and for RASSF1 (0-8%), while a lower value for
CDKN2A (23-67%) was observed [11]. It should be noted
that the studies recently reviewed [11] were conducted on
small populations from different ethnic backgrounds. It is
possible that environmental exposures as well as distinct
genetic pathways to cancer development may explain the
wide range of frequencies reported in the literature [33].
We also analyzed the tumor methylation pattern of the
combination of the three genes under study. We observed
that in roughly half of the tumors, none of the three genes
were methylated, while in a small proportion of the tis-
sues (roughly 10%), at least two of the genes under study
were hypermethylated. This suggests that different car-
cinogenetic pathways may be present in tumors that are
otherwise similar for histology and location. Unfortu-
nately, the small size of the study does not allow any fur-
ther speculation on this issue. CDKN2A was not
methylated in any of the HPV-positive samples. This
observation is consistent with the hypothesis that HPV-
associated head and neck cancers have a distinct etiology,
since HPV-positive tumors are more likely to over-express
p16 [34].
No direct association between promoter hypermethyla-
tion in MGMT or RASSF1 and age, sex, smoking, alcohol
drinking, or tumor stage was observed, in agreement with
recently reported data [16,17,35]. A possible association
between drinking and stage with methylation of CDKN2A
was observed, although small sample size requires confir-
mation of this result. The comparison of the findings in
the tumor tissue and in the peripheral blood from the
same patient showed no RASSF1 or CDKN2A methylation
in any of the peripheral blood samples, and only one sam-
ple positive for MGMT methylation; a T4N0 M0 (stage
IVa) squamous cancer of the oral cavity. Although no
metastasis was identified at diagnosis, it is conceivable
that the positive blood samples were due to circulating
tumor cells from the advanced stage tumor. These results
indicate that hypermethylation is tumor specific and is
not a general characteristic of other tissues or cell types of
the individual at risk for tumor recurrence.
Epigenetic changes in cancer, more recently referred to as
the cancer epigenome, have traditionally been evaluated
by measuring the status of CpG island cytosine methyla-
tion of a particular gene such as MGMT [3] using Methyl-
ation-Specific PCR (MSP-PCR). MSP-PCR is a well-
established, straightforward and rapid PCR-based method
for analysis of promoter methylation and gene silencing.
However, MSP-PCR is not quantitative and therefore it
was of interest to determine whether variable amounts of
MGMT promoter methylation could be detected in these
tumors as a function of biological characteristics of the
tumor. To assess this, a quantitative pyrosequencing
methylation assay was employed. The tumors found to be
positively methylated by methylation-specific PCR indeed
Degree of MGMT promoter methylationFigur 2
Degree of MGMT promoter methylation. The degree 
of methylation at the MGMT promoter was determined by 
pyrosequencing (Pyromark MGMT ID system). Shown are 
the plots of (A) overall patient survival time (months) and 
(B) disease-free survival time (months), according to the 
degree of MGMT methylation (no detectable methylation or 
a level of methylation either greater than or less than 6.9%).Page 8 of 11
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46.6% with a median level of 6.9%. This is in agreement
with the findings of Shaw and colleagues [29], who report
MGMT percent methylation ranging from 0.0%-45%
among 37 head and neck tumor samples. The association
between degree of MGMT hypermethylation and oral and
pharyngeal cancer survival has not been reported before
to our knowledge. Indirect evidence in support of our
findings comes from previous reports on a negative corre-
lation between MGMT mRNA levels and percent pro-
moter methylation in head and neck tumors [26,36].
Conclusion
We evaluated 88 primary oral and pharyngeal tumors for
methylation of the promoter for the DNA repair gene
MGMT and the tumor suppressor genes CDKN2A and
RASSF1 using methylation-specific PCR. Further, quanti-
tative MGMT methylation was assessed and these results
were then correlated with survival and tumor recurrence.
MGMT promoter methylation was significantly associated
with poorer overall and disease-free survival and a signif-
icant trend with the amount of MGMT methylation and
survival and recurrence was observed (ptrend = 0.002 and
0.001 respectively). These results implicate MGMT pro-
moter methylation as a possible biomarker for oral and
pharyngeal cancer prognosis. It is therefore conceivable
that as the degree of methylation in head and neck cancers
increases, genomic stability declines as a result of decreas-
ing MGMT expression, thus leading to poorer prognosis
and tumor recurrence. Further, the altered DNA methyla-
tion landscape of the cancer epigenome is not limited to
promoter hypermethylation of select genes but also
includes global hypomethylation as a prelude to onco-
gene activation and genome instability [7-9]. The critical
role of MGMT in DNA repair suggests that defective DNA
repair may be correlative in the observed association
between MGMT promoter methylation and tumor recur-
rence. We therefore suggest that follow-up studies include
(i) further quantitative methylation analysis, such as the
MethyLight [37-42] or pyrosequencing assay [26,27], (ii)
a measurement of global methylation status in promoters
and non-promoter regions [43] and (iii) a detailed analy-
sis of downstream DNA repair genes regulated by methyl-
ation such as MLH1, MSH2, ATM etc. in an effort to
identify a DNA repair gene methylation signature that
may be responsive to patient outcome.
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MGMT: O6-methylguanine-DNA methyltransferase; MSP-
PCR: Methylation-Specific PCR; HPV: human papilloma-
virus.
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